Concurrent Week1y Cisplatin and Radiation Therapy for High risk group of Uterine Cervical Cancer.
- Author:
Hyun Suk SUH
1
;
Seung Hee KANG
;
Ju Ree KIM
;
Eung Soo LEE
;
Yong Bong KIM
;
Sung Kwan PARK
Author Information
1. Department of Radiation Oncology, Inje University Paik Hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Cervical carcinoma;
Concurrent chemotherapy;
Cisplatin;
Radiation therapy
- MeSH:
Cisplatin*;
Drug Therapy;
Follow-Up Studies;
Humans;
Pelvis;
Survival Rate;
Uterine Cervical Neoplasms*
- From:Journal of the Korean Society for Therapeutic Radiology
1992;10(2):213-218
- CountryRepublic of Korea
- Language:English
-
Abstract:
Locally advanced cervical carcinoma has shown high rate of local failure and poor survival rate despite the advances in modern radiation therapy techniques. Combination of chemotherapy and radiation therapy demonstrated benefit in improving local control and possibly the overall survival. Twelve patients with advanced stages(Figo stage III, IV) or 11b with bulky tumors(>5 cm in diameter) were treated with combination of radiation therapy and concurrent weekly cisplatin between May of 1988 and September of 1991 at Inje University Paik Hospital. Cisplatin was administered in bolus injections of 50mg at weekly intervals during the courses of radiation therapy. Median follow-up period was 34 months with ranges from 3 to 53 months. Eleven patients were evaluable for the estimation of response. Response was noted in all the 11 patients: complete response(CR) in 7(64%), partial response (PR) in 4(36%). Of the 7 patients with CR, all maintained local control, whereas only 1 of 4 with PR showed local control. Six of 7 with CR are alive disease free on the completion of follow-up. Eight of 11 patients (73%) maintained local control in the pelvis. The Median survival for CR patient is 27 months and 9 months for the PR patients. Analysis of survival by stage shows 11 b 4/5, III 2/3 and IV 1/3. Overall survival rate was 61%. Three patients recurred : 1 at local, 1 in distant site and 1 with local and distant site. Toxicity for the combination therapy was not excessive. These results are preliminary, but definitely encouraging in view of markedly improved response rate compared with the results of historical control group.
